Loading clinical trials...
Loading clinical trials...
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma
Conditions
Interventions
pembrolizumab; vorinostat
Locations
14
France
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, France
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre George François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Start Date
October 28, 2020
Primary Completion Date
December 15, 2022
Completion Date
November 26, 2024
Last Updated
February 19, 2025
NCT05607108
NCT05639972
NCT06639191
NCT06447064
NCT06403436
NCT06339827
Lead Sponsor
UNICANCER
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions